World CLL Day with Dr. Anderson
By Mary Ann Anderson, MBBS, PhD - September 13, 2023Mary Ann Anderson, MBBS, PhD, of the Peter MacCallum Cancer Centre in Australia, discusses the importance of World Chronic Lymphocytic Leukemia (CLL) Day.
Advertisement
Related Posts
The primary endpoints of the phase III ELEVATE-RR study were PFS, AEs, and events of clinical interest.
Reseserchers with the German CLL Study Group conducted a prospective analysis of karyotype complexity in patients with CLL.
Patients with mutated IGHV had a median PFS of 14.6 years compared with 4.2 years in patients with unmutated IGHV.
Dr. Coombs discusses her journey into oncology, what it’s like to broach the lymphoid and myeloid worlds, and a unique ...
Othman Al-Sawaf, MD, and Nicole Lamanna, MD, debate approaches in this Point | Counterpoint.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
630 Madison Ave.
Manalapan, NJ 07726
© 2023 Mashup Media, LLC. All rights reserved.